摘要
至第一个线粒体DNA点突变在1988年证实与Leber遗传性视神经病变(LHON)有关以来,已经过去了二十多年。随后,我们对遗传性视神经病变分子基础以及他们的临床特征和发病机制有了相当的了解。很明显,绝大多数的遗传视神经病变有原发性的或间接的影响线粒体功能,证明了“线粒体视神经病变”的定义。尽管这些进展中有许多未解决的特征仍然需要被解释,例如在LHON和显性视神经萎缩(DOA)的不完全外显率和可变的临床表现力,在LHON中的性别患病率和在LHON和DOA中复杂的基因/环境的相互作用。这篇综述的主题是线粒体视神经病变的分子基础的最新研究进展。尤其是我们分析了线粒体生物合成在强调不完全外显率和可变的临床表现补偿机制中的作用,及其在未来治疗方法的可行设计。
关键词: 显性视神经萎缩,环境诱因,基因修饰,Leber遗传性视神经病变,Leber遗传性视神经病变,线粒体DNA,OPA1,视神经病变。
Current Molecular Medicine
Title:Genetic Basis of Mitochondrial Optic Neuropathies
Volume: 14 Issue: 8
Author(s): A. Maresca, L. Caporali, D. Strobbe, C. Zanna, D. Malavolta, C. La Morgia, M.L. Valentino and V. Carelli
Affiliation:
关键词: 显性视神经萎缩,环境诱因,基因修饰,Leber遗传性视神经病变,Leber遗传性视神经病变,线粒体DNA,OPA1,视神经病变。
摘要: Over two decades have elapsed since the first mtDNA point mutation was associated with Leber’s hereditary optic neuropathy (LHON) in 1988. We have subsequently witnessed a substantial understanding of the molecular basis of hereditary optic neuropathies, as well as of their clinical features and pathogenic mechanisms. It became clear that the large majority of genetic optic neuropathies have a primary or an indirect involvement of mitochondrial functions, justifying the definition of “mitochondrial optic neuropathies”. Despite this progress many unsolved features remain to be understood, such as incomplete penetrance and variable clinical expressivity in LHON and dominant optic atrophy (DOA), gender prevalence in LHON, and complex gene/environment interactions in both LHON and DOA. The most recent advancement in our understanding of the molecular basis of mitochondrial optic neuropathies is the topic of this review. In particular, we analyze the role that mitochondrial biogenesis may play in the compensatory mechanisms that underlie incomplete penetrance and clinical expressivity, a scenario relevant for the possible design of future therapeutic approaches.
Export Options
About this article
Cite this article as:
Maresca A., Caporali L., Strobbe D., Zanna C., Malavolta D., Morgia La C., Valentino M.L. and Carelli V., Genetic Basis of Mitochondrial Optic Neuropathies, Current Molecular Medicine 2014; 14 (8) . https://dx.doi.org/10.2174/1566524014666141010132627
DOI https://dx.doi.org/10.2174/1566524014666141010132627 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
New Perspectives in the Pharmacological Treatment of Non-Melanoma Skin Cancer
Current Drug Targets Seeing Genes at Work in the Living Brain with Non-Invasive Molecular Imaging
Current Gene Therapy Key miRNAs in Modulating Aging and Longevity: A Focus on Signaling Pathways and Cellular Targets
Current Molecular Pharmacology Neurological Involvement in Rheumatoid Arthritis
Current Immunology Reviews (Discontinued) SiRNA Mediated Gene Silencing: Hurdles, Strategies and Applications
Pharmaceutical Nanotechnology Peroxisome Proliferator-Activated Receptor γ Agonists as Insulin Sensitizers: From the Discovery to Recent Progress
Current Topics in Medicinal Chemistry Ocular Toxicities in Cancer Therapy: Still Overlooked
Current Cancer Therapy Reviews Calpains: Attractive Targets for the Development of Synthetic Inhibitors
Current Topics in Medicinal Chemistry Drug Therapy of Neuropathic Pain: Current Developments and Future Perspectives
Current Drug Targets Molecular Pathophysiology of Cavernous Nerve Injury and Identification of Strategies for Nerve Function Recovery After Radical Prostatectomy
Current Drug Targets Melatonin Leads to Axonal Regeneration, Reduction in Oxidative Stress, and Improved Functional Recovery Following Sciatic Nerve Injury
Current Neurovascular Research Patent Selections
Recent Patents on Inflammation & Allergy Drug Discovery Involvement of Orbital Structures in Rheumatic Disease
Current Rheumatology Reviews Common Genetic Conditions of Ischemic Stroke to Keep in Mind
Current Molecular Medicine Ocular Complications of Drugs Used in Rheumatic Disease
Current Rheumatology Reviews Poly(ADP-Ribose) Polymerase Inhibitors: New Pharmacological Functions and Potential Clinical Implications
Current Pharmaceutical Design PDE5 Inhibitors in Non-Urological Conditions
Current Pharmaceutical Design Rho-kinase (ROCK) Inhibitors - A Neuroprotective Therapeutic Paradigm with a Focus on Ocular Utility
Current Medicinal Chemistry Biological Relevance of Lysophospholipids and Green Solutions for Their Synthesis
Current Organic Chemistry Glutamate in CNS Neurodegeneration and Cognition and its Regulation by GCPII Inhibition
Current Medicinal Chemistry